Financial Performance - Revenue for the year ended December 31, 2022, was HKD 440.316 million, representing a 24.6% increase from HKD 353.405 million in 2021[13]. - Gross profit for the same period was HKD 334.883 million, with a gross margin of 76.1%, down from 78.4% in the previous year[13][18]. - The company achieved a historical revenue high in 2022, with a year-on-year increase of 24.6% despite challenges from the COVID-19 pandemic[39]. - The company recorded a record revenue of approximately HKD 440.3 million for the year 2022, representing a significant year-on-year growth of 24.6% from HKD 353.4 million in 2021[69]. - The company achieved a net profit of approximately HKD 38.5 million in 2022, a substantial increase of 296.6% compared to a loss of HKD 19.6 million in 2021[70]. - The sales cost increased by 38.0% to approximately HKD 105.4 million in 2022, up from about HKD 76.4 million in 2021, while gross profit rose by 20.9% to approximately HKD 334.9 million[69]. - The gross margin for 2022 was 76.1%, slightly down from 78.4% in 2021[69]. Research and Development - Research and development expenses were HKD 35.781 million, accounting for 8.1% of revenue, a decrease from 14.2% in 2021[13][19]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals and high-value generic drugs at various stages of development[44]. - The company is committed to enhancing its R&D capabilities and has partnered with Oran Biomedicine and DotBio to explore new applications for cell-penetrating protein technology[96]. - The company is researching oral delivery innovations for peptide drugs, with the third-generation Uni-PTH product showing promise in enhancing competitiveness in the endocrine field[97]. - The company is developing new products such as sodium diquafosol eye drops, which are expected to provide a new clinical treatment option for dry eye patients in China[91]. Product Development and Market Strategy - The company has two new prescription drugs, Uni-E4 and Uni-PTH, that have completed clinical trials, targeting type 2 diabetes and osteoporosis respectively[10][11]. - The company launched a new product, 博固泰®, expected to receive market approval by September 2023, marking its fifth self-developed drug[26]. - The new drug application for Bogutai® (teriparatide injection) was accepted by the National Medical Products Administration, preparing for entry into the osteoporosis market[41]. - The company is preparing for a national centralized procurement for Pinapu® in April 2023, aiming to secure its position in future procurements[27]. - The product BoguTai® is anticipated to receive market approval by September 2023, aiming to capture a significant share of the projected $81.5 billion osteoporosis market in China by 2031[92]. Market Performance - The company successfully captured nearly 50% market share for its product, Pinapu®, significantly outperforming competitors in sales[27]. - The flagship product, Jin Yin Peptide®, generated revenue of approximately HKD 169.4 million in 2022, a slight decline of 0.6% from HKD 170.5 million in 2021[72]. - The proprietary biological drugs generated sales of approximately HKD 207.8 million, a growth of 0.5% compared to the previous year, accounting for 47.2% of total sales[78]. - The proprietary chemical drugs, including Pinafu® and Boshu Tai®, achieved revenue of approximately HKD 232.5 million, a substantial increase of 58.5% year-on-year[79]. Corporate Governance - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[139]. - The company has adopted all applicable corporate governance codes as per the listing rules, demonstrating its commitment to transparency and accountability[138]. - The independent non-executive directors are confirmed to meet independence criteria, ensuring unbiased judgment in strategic decisions[141]. - The company emphasizes maintaining and improving corporate governance quality to enhance investor confidence and ensure stable growth[137]. - The board is responsible for determining the company's corporate governance policies and ensuring compliance with legal and regulatory requirements[170]. Financial Health and Ratios - The cash ratio improved to 1.09 from 0.91, and the current ratio increased to 2.22 from 2.18[15]. - The debt-to-equity ratio decreased to 50.2% from 53.5%[15]. - Total asset turnover improved to 150.6% from 132.1%[15]. - As of December 31, 2022, the company's cash and bank balances were approximately HKD 98.22 million, with total assets of approximately HKD 292.47 million[99]. - The company's current liabilities as of December 31, 2022, were approximately HKD 90.26 million, resulting in a current liabilities to total assets ratio of 30.9%[99]. Management and Leadership - The company has a strong management team with members holding advanced degrees from prestigious institutions, including Peking University and the University of Hartford[126][127]. - The management team has a combined experience of over 100 years in various sectors, including finance, consulting, and corporate governance[128][130]. - The company appointed Mr. Liang Guolong as Executive Director and Chairman of the Board since January 13, 2017, with extensive experience in investment banking and biotechnology[122]. - Mr. Zhao Zhigang has been the CEO since April 8, 2019, and has over 20 years of experience in corporate finance and auditing, previously serving as CFO for several listed companies[124]. - The company has appointed Mr. Du Kai as the Chief Financial Officer, effective March 31, 2022, bringing over 17 years of financial and tax experience, particularly in the biopharmaceutical industry[132]. Employee and Talent Management - The company employed 370 staff members as of December 31, 2022, with a focus on competitive compensation to attract and retain talent[101]. - The company has achieved gender diversity among employees, with a male-to-female ratio improving from 70:100 last year to 100:100[181]. - The board currently consists entirely of male members, but the company aims to appoint female directors to meet diversity requirements by December 31, 2024, targeting a female representation of over 10%[180]. Compliance and Ethics - The company emphasizes high standards of business ethics and integrity, requiring all employees to adhere to a long-established code of conduct[198]. - The group has established business codes for all manufacturers and suppliers, ensuring safe and healthy workplaces and fair recruitment practices[198]. - The company closely monitors compliance with the codes of conduct set by major licensors and customers for its manufacturers and suppliers[198]. Future Outlook - The company anticipates that the pharmaceutical and healthcare industry in China will continue to thrive due to aging population, domestic substitution, and supportive policies[87]. - The company plans to continue focusing on gender diversity among employees to enhance its future competitiveness[181]. - The company is committed to ongoing research and development of new products and technologies to drive future growth[130].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就 因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 之 末 期 業 績 公 佈 截至二零二二年十二月三十一日止年度摘要 • 截至二零二二年十二月三十一日止年度（「年內」），本集團營業額創 新高，達到440.3百萬港元，按年（「按年」）顯著增長24.6%。 • 年 內，本 集 團 扭 虧 為 盈，盈 利38.5百 萬 港 元，按 年 大 幅 增 長296.6%， 成為一家研究型生物製藥公司的重要里程碑。 • 匹 納 普®及 及 博 舒 泰®的 銷 售 表 現 異 常 出 色，按 年 分 別 增 長51.2%及 292.5%。 ...

I 聯康集團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司 (於開疊联島註冊成立之有限公司) 。 (股份代號:0690) 中 期 報 告 創 造 . . LEADING GENUINE INNOVATION · · . . . . . 。 . 29 /6 / . 1 7 . . o // . -HD 1 . . . BO 目 錄 主要財務摘要 管理層討論及分析 簡明綜合損益及其他全面收益表 簡明綜合財務狀況表 簡明綜合現金流量表 簡明綜合權益變動表 簡明綜合財務報表附註 其他資料 公司資料 6 29 31 33 34 36 .57 非執行董事 核數師 邱國榮先生 香港立信德豪會計師事務所有限公司 執業會計師 獨立非執行董事 周啓明先生 註冊辦事處 任啓民先生 Cricket Square 馬青山先生 Hutchins Drive P.O. Box 2681 審核委員會 Grand Cayman, KY1-1111 周啓明先生(審核委員會主席) Cayman Islands 任啓民先生 馬青山先生 總辦事處兼香港主要營業地點 香港 薪酬委員會 新 ...

聯康集團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯 康 生 物 科 技 集團有限公 司 (於開曼群島註冊成立之有限公司) 股份代號：0690 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------|-------|-------|----------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 創 造 | 新 臂 LEADING GENUINE INNOVATION | 藥 | | --- | --- | --- | --- | --- | --- | --- | |-------|-- ...

图 th R, 剧 道 展 LEADING GENUINE INNOVATION 聯 康 集 團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司 (於開曼群島註冊成立之有限公司) (股份代號 : 0690) 2 Q y . Har . . ● ● . 0 -- . e 9 a A . . / -- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目錄 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 公司資料 | | | | | | | | | ...

心 創造 新 醫藥 LEADING GENUINE INNOVATION IFULO I - 8 GHT 年 報 2020. ●●康集團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司 : (於開曼群島註冊成立之有限公司) (股份代號 : 0690) AGILE ACCELERATED GROWTH INTERNATIONAL EXECUTION 我們建立一個名為AGILE的五年計劃，所謂AGILE 就是：「促進增長，國際視野」。 根基穩固 建構未來 追求卓越營運乃聯康的重中之重。我們將繼續致 力改善並發展本公司現有基建，讓穩固的根基為 我們帶來強勁增長前景。 使命 聯康生物科技集團專注於為全中國病患者帶來創 新和高素質的醫療保健方案，並且負責任地經 營，為我們的股東帶來持續增長的價值。 願景 聯康生物科技集團銳意成為全球領先的生物製藥 公司，專注於透過創新及開展戰略合作滿足中國 醫療保健市場的需求。 致力成為全球醫藥公司為中國患者引進優質醫療 道路上的首選伙伴。 | --- | --- | --- | --- | --- | --- | --- ...

S 聯 康 集 團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司 (於開曼群島註冊成立之有限公司) (股份代號 : 0690) 中期 報告 2020 新 創 造 臂 藥 LEADING GENUINE INNOVATION ● � . ● . . . ● . . ● i r . . 0 i D - · T � � t the first of · C in the . . .. . . te . ● . 目錄 2 公司資料 3 主要財務摘要 5 管理層討論及分析 17 簡明綜合損益及其他全面收益表 18 簡明綜合財務狀況表 20 簡明綜合現金流量表 21 簡明綜合權益變動表 23 簡明綜合財務報表附註 39 其他資料 | --- | --- | |---------------------------------------------------------------------------|------------------------------------------------------------| | | | | 公司資料 ...

S 聯 康 集 團 Uni-Bio Science Uni-Bio Science Group Ltd. ▪ 聯康生物科技集團有限公司 (於開曼群島註冊成立之有限公司) (股份代號 : 0690) 0 事 十 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|------------|-------|---------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | + | | | | | | | | | | | | | | | | 中 | + | | 4 | | | | | | | | | | | | 4 | E | | | | | | | | | | | | | | | | | + ...

聯康集團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司 (於開曼群島註冊成立之有限公司) 股份代號:0690 創 造 新 Re 醫 藥 LEADING GENUINE INNOVATION 2019 中期報告 2019年06月21日聯康集團榮膺兩項2019中國融 資大獎「卓越科技創新企業」與「最具潛力上市公 司」 2019年1月聯康集團生物創新制劑－無菌 液體注射劑卡式瓶╱預灌封生產線正式投 入使用 2019年上半年聯康生物科技集團成功引入國資 背景在港投方建立長期戰略合作，並於2019年 8月6日通過一般授權發行新股增資完畢 目錄 2 公司資料 3 主要財務摘要 5 管理層討論及分析 19 簡明綜合損益及其他全面收益表 20 簡明綜合財務狀況表 22 簡明綜合現金流量表 23 簡明綜合權益變動表 25 簡明綜合財務報表附註 48 其他資料 | --- | --- | |---------------------------------------------|------------------------------------------ ...

聯 康 集 團 Uni-Bio Science Uni-Bio Science Group Ltd. 聯康生物科技集團有限公司* (於開曼群島註冊成立之有限公司) 股份代號 : 0690 新 創 造 獎 臂 LEADING GENUINE INNOVATION 2018 年度報告 ี 値供識別 ACCELERATED GROWTH AGILE INTERNATIONAL EXECUTION 我們建立一個名為AGILE的五年計劃，所謂AGILE就是： 「促進增長，國際視野」。 | --- | --- | --- | --- | --- | --- | --- | |-------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------|-------|------------------------------------------ ...